A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo...

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Congenital muscular dystrophy (CMD) comprises inherited muscle disorders presenting with infantile hypotonia and weakness.
• While numerous causative genes are known, some CMD cases remain genetically undefined.
• Specific CMD subtypes exhibit distinct pathological features, including unique mitochondrial abnormalities.

Purpose of the Study:

• To investigate the molecular basis of a CMD subtype characterized by early-onset muscle wasting, intellectual disability, and peripheral enlarged mitochondria.
• To identify the genetic cause in 15 individuals with this specific CMD phenotype.
• To elucidate the functional consequences of identified mutations on cellular pathways.

Main Methods:

• Genetic analysis of 15 individuals with a distinct CMD phenotype.
• Identification of homozygous or compound heterozygous mutations in the choline kinase beta (CHKB) gene.
• Biochemical assays measuring choline kinase activity and phosphatidylcholine levels in affected individuals.

Main Results:

• Mutations in the CHKB gene were identified as the cause of this CMD subtype.
• Choline kinase activity was absent, and phosphatidylcholine levels were reduced in patients with nonsense mutations.
• This study links disruption of the phosphatidylcholine de novo biosynthetic pathway to a human muscular and neurological disorder.

Conclusions:

• The CHKB gene is crucial for phosphatidylcholine biosynthesis, essential for normal muscle and brain development.
• Defects in phospholipid metabolism represent a novel mechanism underlying congenital muscular dystrophy.
• This research provides a molecular explanation for a previously unresolved group of congenital muscular dystrophy patients.